Back to top
more

Curaleaf Holdings, Inc. (CURLF)

(Delayed Data from OTC)

$1.92 USD

1.92
2,171,856

+0.27 (16.36%)

Updated Aug 5, 2025 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sundeep Ganoria headshot

Should You Buy, Hold or Sell TLRY Stock Post Q4 Earnings Release?

by Sundeep Ganoria

Tilray posts record non-cannabis revenues in fiscal 2025, but Q4 sales slip as cannabis weakness pressures overall results.

Zacks Equity Research

Baxter International (BAX) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of -1.67% and -0.28%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Sundeep Ganoria headshot

Cannabis Operator CRLBF Plans California Exit: How to Play the Stock?

by Sundeep Ganoria

Cresco plans to exit California, citing tough market dynamics, as it sharpens focus on high-margin growth markets.

Sundeep Ganoria headshot

Cannabis Operator Green Thumb Down 30% YTD: Time to Buy, Sell or Hold?

by Sundeep Ganoria

GTBIF slides 30% YTD as rising costs, flat revenues and tight U.S. rules weigh on margins and investor sentiment.

Sundeep Ganoria headshot

Cannabis Operator Curaleaf Plunges 46% YTD: Time to Sell or Hold?

by Sundeep Ganoria

CURLF dives 46% YTD as domestic headwinds outweigh global growth; is it time to cash out or wait for a rebound?

Sundeep Ganoria headshot

Could the New Federal Bill Derail the U.S. Hemp Industry?

by Sundeep Ganoria

A proposed federal bill could upend the U.S. hemp market, threatening CBD and Delta-8 products now sold nationwide.

Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) delivered earnings and revenue surprises of 0% and 0.49%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) Q4 Earnings Top Estimates

by Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) delivered earnings and revenue surprises of 128.57% and 0.25%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Perrigo (PRGO) Q4 Earnings Beat Estimates

by Zacks Equity Research

Perrigo (PRGO) delivered earnings and revenue surprises of 1.09% and 4.77%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Aurora Cannabis (ACB) delivered earnings and revenue surprises of 50% and 9.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) delivered earnings and revenue surprises of -16.67% and 4.42%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -74.84% and 4.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stryker (SYK) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Stryker (SYK) delivered earnings and revenue surprises of 3.24% and 2.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zynex Inc. (ZYXI) Tops Q3 Earnings Estimates

by Zacks Equity Research

Zynex (ZYXI) delivered earnings and revenue surprises of 40% and 0.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) delivered earnings and revenue surprises of -20% and 0.66%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Curaleaf Holdings, Inc. (CURLF) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Central Garden (CENTA) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Central Garden (CENTA) delivered earnings and revenue surprises of 19.28% and 0.49%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) Surges 24.6%: Is This an Indication of Further Gains?

by Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Snap-On (SNA) Q1 Earnings Top Estimates

by Zacks Equity Research

Snap-On (SNA) delivered earnings and revenue surprises of 1.93% and 0.98%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) delivered earnings and revenue surprises of 80% and 2.56%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Neena Mishra headshot

Cannabis ETFs: What's Behind the Latest Surge

by Neena Mishra

While marijuana ETFs have seen a recent surge, investors should be aware of the potential risks

Zacks Equity Research

Will Curaleaf Holdings, Inc. (CURLF) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sweta Killa headshot

Inside the Best-Performing ETF of Q3

by Sweta Killa

Roundhill Cannabis ETF (WEED) topped the list of the best-performing ETFs of the third quarter with impressive returns of about 49%.

Neena Mishra headshot

Cannabis Stocks & ETFs: Can the Recent Surge Continue?

by Neena Mishra

CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.

Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Curaleaf Holdings, Inc. (CURLF) delivered earnings and revenue surprises of -75% and 0.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?